These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22275828)

  • 21. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.
    Denis P; Baudouin C; Bron A; Nordmann JP; Renard JP; Rouland JF; Sellem E; Amrane M
    BMC Ophthalmol; 2010 Feb; 10():4. PubMed ID: 20181282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment.
    Cheng YH; Tsai TH; Jhan YY; Chiu AW; Tsai KL; Chien CS; Chiou SH; Liu CJ
    Carbohydr Polym; 2016 Jun; 144():390-9. PubMed ID: 27083831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
    Day DG; Hollander DA
    Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
    PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma.
    Rulo AH; Greve EL; Geijssen HC; Hoyng PF
    Ophthalmology; 1996 Aug; 103(8):1276-82. PubMed ID: 8764799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma.
    Fathalla D; Fouad EA; Soliman GM
    Drug Dev Ind Pharm; 2020 May; 46(5):806-813. PubMed ID: 32281424
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance.
    Rodriguez-Aller M; Guinchard S; Guillarme D; Pupier M; Jeannerat D; Rivara-Minten E; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):203-14. PubMed ID: 25960331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.
    Schwenn O; Heckmann B; Guzy C; Miller PJ
    BMC Ophthalmol; 2010 Sep; 10():21. PubMed ID: 20825668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
    Eveleth D; Starita C; Tressler C
    BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension].
    Baudouin C; Rouland JF; Nordmann JP; Bron A; Pelen F
    J Fr Ophtalmol; 2006 Jun; 29(6):615-24. PubMed ID: 16885890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peak pressures: crossover study of timolol and latanoprost.
    Sihota R; Saxena R; Agarwal HC; Pandey RM; Gulati V
    Eur J Ophthalmol; 2003 Jul; 13(6):546-52. PubMed ID: 12948313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB; Podos SM; Kitazawa Y; Wang RF
    Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
    Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
    Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.